3772-13-2

Basic information

• Product Name: ISOBUTYLENE SULFIDE
• Synonyms: ISOBUTYLENE SULFIDE;2,2-DIMETHYLETHYLENE SULFIDE;2,2-DIMETHYLTHIIRANE;2-METHYLPROPYLENE SULFIDE;2,2-Dimethylthiacyclopropane;2,2-Dimethylethylene Sulfide 2,2-Dimethylthiirane 2-Methylpropylene Sulfide
• CAS NO: 3772-13-2
• Molecular Formula: C₄H₈S
• Molecular Weight: 88.17
• Product Categories: Simple 3-Membered Ring Compounds;Sulfur Compounds (for Synthesis);Synthetic Organic Chemistry;Thiiranes
• Mol File: 3772-13-2.mol

Chemical Properties

• Boiling Point: 86°C
• Appearance: /
• Density: 0,9 g/cm3
• Refractive Index: 1.4620 to 1.4650
• Storage Temp.: Refrigerator
• CAS DataBase Reference: ISOBUTYLENE SULFIDE(CAS DataBase Reference)
• NIST Chemistry Reference: ISOBUTYLENE SULFIDE(3772-13-2)
• EPA Substance Registry System: ISOBUTYLENE SULFIDE(3772-13-2)

Safety Data

• Statements: 11-23/24/25
• Safety Statements: 16-26-33-36/37/39
• RIDADR: 1993
• HazardClass: 3
• PackingGroup: II
• Hazardous Substances Data: 3772-13-2(Hazardous Substances Data)

Usage

Uses

Used in Chemical Production Industry:
Isobutylene sulfide is used as a chemical intermediate for the synthesis of other chemicals, contributing to the production of a wide range of compounds.
Used in Rubber Industry:
It serves as a catalyst in rubber vulcanization, a process that enhances the elasticity, strength, and durability of rubber products.
Used in Cellophane Production:
Isobutylene sulfide is utilized in the manufacturing process of cellophane, a thin, transparent sheet of cellulose used for packaging and wrapping.
Used in Pharmaceutical Industry:
It is employed in the production of certain pharmaceuticals, playing a crucial role in the synthesis of specific drug compounds.
Used as a Specialty Solvent:
Isobutylene sulfide is used as a specialty solvent in various industrial applications, taking advantage of its unique properties to dissolve specific substances or facilitate particular chemical reactions.

Upstream product

• 558-30-5 2-methyl-1,2-epoxypropane 
• 333-20-0 potassium thioacyanate 
• 17356-08-0 thiourea 
• 558-42-9 3-chloro-2-methylpropan-2-ol 

Downstream Products

• 73419-17-7 2-isopropyl-6,6-dimethyl-[1,3,4]thiadiazinane 
• 100318-04-5 1-Dimethylamino-2-methyl-propanthiol-(2) 
• 85878-49-5 dimethyl-8,8 thia-7 aza-1 bicyclo<4.3.0>nonane 
• 82605-97-8 3-Ethyl-5,5-dimethyl-2-phenyl-thiazolidine 
• 13640-71-6 2-methyl-1-(phenylthio)-1-propene 
• 88476-41-9 2-chloro-2-methyl-1-propyl phenylthiolcarbamate 
• 88476-40-8 1-chloro-2-methyl-2-propyl phenylthiolcarbamate 
• 88476-37-3 2-bromo-2-methyl-1-propyl phenylthiolcarbamate 
• 107479-59-4 2-amino-3-ethoxycarbonyl-5,5-dimethyl-4,5-dihydrothiophene 
• 145144-10-1 N-(2-mercapto-2-methylpropyl)-1,2-benzenediamine 
• 260268-16-4 2-Methyl-1-piperazinylpropane-2-thiol 
• 140231-31-8 4-mercapto-4-dimethylpentanoic acid 
• 1171909-28-6 2-[(2-fluorophenyl)amino]-2-methylpropane-1-thiol 
• 1171909-25-3 1-[(2-fluorophenyl)amino]-2-methylpropane-2-thiol 

Relevant articles and documents

Identification, synthesis, and conformation of tri- and tetrathiacycloalkanes from marine bacteria

(Chemical Equation Presented) Seven new cyclic natural polysulfides 1-7 were identified in extracts of two bacterial Cytophaga strains (CFB-phylum) isolated from biofilms from the North Sea. Their structures are based on mono- and dimericcyclization products of 2-methylpropane-1,2-dithiol 8, which was also present in the extract in trace amounts. The structures were deduced by analysis of their mass spectra and confirmed by synthesis. The 1 H NMR spectra of some these compounds suggested a high flexibility of the trithiepane and tetrathiocane systems. Therefore, their conformation was further analyzed by DFT calculations and dynamic NMR spectroscopy. While thiepane 4 possesses a twist-chair lowest energy conformation, its isomers 2 and 3 adopt a chairlike conformation, as does the tetrathiocane 5. In contrast, tetrathiocane 6 favors again a twisted chair conformation.

Carboxylic acid compound and preparation method and use thereof

The present invention relates to the technical field of medicines, and particularly relates to a carboxylic acid compound shown as a chemical formula I or formula II, a pharmaceutically acceptable salt, a prodrug, a solvate and a preparing method thereof,

Nitric oxide donors, compositions and methods of use related applications

The invention describes novel nitric oxide donors and novel compositions comprising at least one nitric oxide donor. The invention also provides novel compositions comprising at least one nitric oxide donor, and, optionally, at least one therapeutic agent. The compounds and compositions of the invention can also be bound to a matrix. The invention also provides methods for treating cardiovascular diseases, for the inhibition of platelet aggregation and platelet adhesion caused by the exposure of blood to a medical device, for treating pathological conditions resulting from abnormal cell proliferation; transplantation rejections, autoimmune, inflammatory, proliferative, hyperproliferative, vascular diseases; for reducing scar tissue or for inhibiting wound contraction, particularly the prophylactic and/or therapeutic treatment of restenosis by administering the nitric oxide donor optionally in combination with at least one therapeutic agent. The invention also provides methods for treating inflammation, pain, fever, gastrointestinal disorders, respiratory disorders and sexual dysfunctions. The nitric oxide donors donate, transfer or release nitric oxide, and/or elevate endogenous levels of endothelium-derived relaxing factor, and/or stimulate endogenous synthesis of nitric oxide and/or are substrates for nitric oxide synthase and are capable of releasing nitric oxide or indirectly delivering or transferring nitric oxide to targeted sites under physiological conditions. The therapeutic agent can optionally be substituted with at least one NO and/or NO2 group (i.e., nitrosylated and/or nitrosated). The invention also provides novel compositions and kits comprising at least one nitric oxide donor and/or at least one therapeutic agent.

Nitrosated and nitrosylated nonsteroidal antiinflammatory compounds, compositions and methods of use

The present invention describes novel nitrosated and/or nitrosylated nonsteroidal antiinflammatory compounds, and novel compositions comprising at least one nitrosated and/or nitrosylated nonsteroidal antiinflammatory compound, and, optionally, at least o

Pesticidal compositions containing phosphoric esters and divalent sulphur compounds

Pesticidal composition comprising: a pesticidal, phosphoric ester the molecule of which has at least one alkyl group of 1 to 3 carbon atoms, 0.05 to 10% of an agent stabilizing the said ester against decomposition by protonisation, together with adjuvants characterized in that the stabilizing agent comprises at least one sulphur compound containing per molecule at least one divalent sulphur atom of which one valence is bonded to an atom chosen from sulphur, carbon, nitrogen, hydrogen, and metals capable of giving a salt, the other valence being bonded to an atom chosen from hydrogen, the carbon atom already noted, a second carbon atom, the nitrogen atom already noted, a second nitrogen atom, the metal atom already noted in the case of a metal of valence greater than one, a second atom of metal and oxygen when the first valence is not attached to an atom of hydrogen, the proportion of sulphur calculated with reference to the weight of the sulphur compound being between 5 and 99%. Process for stabilizing a phosphoric ester of which the molecule possesses at least one alkyl group containing 1 to 3 carbon atoms characterized in that there is added to the phosphoric ester or to a mixture which contains it, 0.05 to 10% calculated on the weight of the phosphoric acid ester of an agent capable of stabilizing the said phosphoric ester against protonisation and comprising at least one sulphur compound such as that defined thereupon.